JKJulie S. Kim

Julie S. Kim

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Julie S. Kim has a total of 21 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Development of a microneedle patch for delivery of mRNA-lipid nanoparticles

    by Sophia H. Sakers, B. Pradeep K. Reddy, Gianna Fiduccia, Katherine E. Byrne, Ingrid Stén, Julie Kim, Afsane Radmand, James E. Dahlman, Mark R. Prausnitz

    MRNA delivered by microneedle patch (MNP) can enable painless delivery, reduced need for healthcare expertise, and improved thermostability. In this study, we investigated formulation and manufacturing approaches for developing MNPs that deliver mRNA-loaded lipid nanoparticles (LNPs) encoding luciferase as a reporter protein during MNP fabrication and storage, including mRNA-LNP concentration, formulation, pH, excipients, and backing material. MNPs were assessed for mRNA-LNP size, encapsulation efficiency, and protein expression in vitro and in vivo. MNPs fabricated with mRNA-LNPs initially prepared at a higher concentration yielded superior expression compared to mRNA-LNP concentration by centrifugation or tangential flow filtration. Acidic pH during MNP manufacturing enabled greater expression in vitro. However, no such correlation was observed in vivo. Polyvinyl alcohol (PVA) best stabilized mRNA-LNPs during the MNP manufacturing process amongst the tested polymers. Incorporating sugars in MNPs did not further improve stability. Low temperature drying (5 °C) preserved mRNA functionality better compared to drying at 25 °C and 40 °C. Though there was significant activity loss initially (87% loss in 2 days at 40 °C), mRNA expression was stabilized for extended subsequent periods even at accelerated conditions (10% additional loss after 28 days at 40 °C). Our systematic approach identified key parameters for successful formulation and manufacturing approaches to incorporate mRNA-LNPs into MNPs, which could expand access to mRNA-based medical interventions.


  • Open Access

    Lipid nanoparticle structure and delivery route during pregnancy dictate mRNA potency, immunogenicity, and maternal and fetal outcomes

    by Namit Chaudhary, Alexandra N. Newby, Mariah L. Arral, Saigopalakrishna S. Yerneni, Samuel T. LoPresti, Rose Doerfler, Daria M. Strelkova Petersen, Catalina Montoya, Julie S. Kim, Bethany Fox, et al.

    Treating pregnancy-related disorders is exceptionally challenging because the threat of maternal and/or fetal toxicity discourages the use of existing medications and hinders new drug development. One potential solution is the use of lipid nanoparticle (LNP) RNA therapies, given their proven efficacy, tolerability, and lack of fetal accumulation. Here, we describe LNPs for efficacious mRNA delivery to maternal organs in pregnant mice via several routes of administration. In the placenta, our lead LNP transfected trophoblasts, endothelial cells, and immune cells, with efficacy being structurally dependent on the ionizable lipid polyamine headgroup. Next, we show that LNP-induced maternal inflammatory responses affect mRNA expression in the maternal compartment and hinder neonatal development. Specifically, pro-inflammatory LNP structures and routes of administration curtailed efficacy in maternal lymphoid organs in an IL-1β-dependent manner. Further, immunogenic LNPs provoked the infiltration of adaptive immune cells into the placenta and restricted pup growth after birth. Together, our results provide mechanism-based structural guidance on the design of potent LNPs for safe use during pregnancy.


  • 2 Money Matters in Immigrant Motherhood

    by Julie S. Kim

    2 Money Matters in Immigrant Motherhood was published in Redefining Multicultural Families in South Korea on page 52.